KEYNOTE-585 China Extension study, NCT04882241: Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension |
|
|
| Active, not recruiting | 3 | 120 | RoW | Pembrolizumab, MK-3475, KEYTRUDA®, Placebo, Normal saline solution, Cisplatin, PLATINOL®, Capecitabine, XELODA®, 5-fluorouracil, ADRUCIL®, 5FU, Docetaxel, TAXOTERE®, Oxaliplatin, ELOXATIN®, Leucovorin, WELLCOVORIN® | Merck Sharp & Dohme LLC | Gastric Cancer, Gastroesophageal Junction Cancer | 02/24 | 04/25 | | |
NCT05180734: PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer |
|
|
| Active, not recruiting | 3 | 878 | RoW | JS001/Placebo, Postoperative Adjuvant Chemotherapy, JS001/placebo combine with Postoperative Adjuvant Chemotherapy | Shanghai Junshi Bioscience Co., Ltd. | Gastric or Esophagogastric Junction Adenocarcinoma | 06/26 | 07/28 | | |
NCT05356520: Comparison of Different Operations for Siewert Type II Adenocarcinoma of Esophagogastric Junction |
|
|
| Recruiting | N/A | 212 | RoW | Endoscopy Ivor-lewis, Laparoscopic transabdominal enlarged gastrectomy | Xijing Hospital of Digestive Diseases, Tang-Du Hospital, Henan Provincial People's Hospital, General Hospital of Ningxia Medical University, First Affiliated Hospital Xi'an Jiaotong University, The First Affiliated Hospital of Shanxi Medical University | Siewert Type II Adenocarcinoma of Esophagogastric Junction | 05/25 | 05/28 | | |
